{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:38:36Z","timestamp":1790519916191,"version":"4.1.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2018,7,30]],"date-time":"2018-07-30T00:00:00Z","timestamp":1532908800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000774","name":"Newcastle University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000774","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s00467-018-4025-0","type":"journal-article","created":{"date-parts":[[2018,7,30]],"date-time":"2018-07-30T00:28:01Z","timestamp":1532910481000},"page":"1485-1492","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Eculizumab in the treatment of Shiga toxin haemolytic uraemic syndrome"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9852-0095","authenticated-orcid":false,"given":"Patrick R.","family":"Walsh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,30]]},"reference":[{"key":"4025_CR1","doi-asserted-by":"publisher","first-page":"590","DOI":"10.3201\/eid1104.040833","volume":"11","author":"RM Lynn","year":"2005","unstructured":"Lynn RM, O'Brien SJ, Taylor CM, Adak GK, Chart H, Cheasty T, Coia JE, Gillespie IA, Locking ME, Reilly WJ, Smith HR, Waters A, Willshaw GA (2005) Childhood hemolytic uremic syndrome, United Kingdom and Ireland. Emerg Infect Dis 11:590\u2013596","journal-title":"Emerg Infect Dis"},{"key":"4025_CR2","first-page":"1073","volume":"365","author":"PI Tarr","year":"2005","unstructured":"Tarr PI, Gordon CA, Chandler WL (2005) Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 365:1073\u20131086","journal-title":"Lancet"},{"key":"4025_CR3","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1136\/archdischild-2017-314264","volume":"103","author":"PR Walsh","year":"2018","unstructured":"Walsh PR, Johnson S (2018) Treatment and management of children with haemolytic uraemic syndrome. Arch Dis Child 103:285\u2013291","journal-title":"Arch Dis Child"},{"key":"4025_CR4","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1053\/j.ajkd.2016.10.006","volume":"68","author":"MA Lusco","year":"2016","unstructured":"Lusco MA, Fogo AB, Najafian B, Alpers CE (2016) Atlas of renal pathology: thrombotic microangiopathy. Am J Kidney Dis 68:e33\u2013e34","journal-title":"Am J Kidney Dis"},{"key":"4025_CR5","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1055\/s-0042-108444","volume":"228","author":"J Matthies","year":"2016","unstructured":"Matthies J, Hunseler C, Ehren R, Volland R, Korber F, Hoppe B, Weber LT, Habbig S (2016) Extrarenal manifestations in Shigatoxin-associated haemolytic uremic syndrome. Klin Padiatr 228:181\u2013188","journal-title":"Klin Padiatr"},{"key":"4025_CR6","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/S0031-3955(16)40096-9","volume":"42","author":"RL Siegler","year":"1995","unstructured":"Siegler RL (1995) The hemolytic uremic syndrome. Pediatr Clin N Am 42:1505\u20131529","journal-title":"Pediatr Clin N Am"},{"key":"4025_CR7","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/ana.410190120","volume":"19","author":"KJ Sheth","year":"1986","unstructured":"Sheth KJ, Swick HM, Haworth N (1986) Neurological involvement in hemolytic\u2013uremic syndrome. Ann Neurol 19:90\u201393","journal-title":"Ann Neurol"},{"key":"4025_CR8","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1542\/peds.2005-0785","volume":"117","author":"RS Oakes","year":"2006","unstructured":"Oakes RS, Siegler RL, McReynolds MA, Pysher T, Pavia AT (2006) Predictors of fatality in postdiarrheal hemolytic uremic syndrome. Pediatrics 117:1656\u20131662","journal-title":"Pediatrics"},{"key":"4025_CR9","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1007\/s00467-015-3147-x","volume":"30","author":"CJ Cobe\u00f1as","year":"2015","unstructured":"Cobe\u00f1as CJ, Bresso PS, Lombardi LL, Amoreo OR, Ruscasso JD, Spizzirri AP, Del C, Suarez \u00c2, Zalba JH, Rahman RC, Risso P (2015) Relationship between red blood cell transfusion requirements and severity of renal disease during the acute stage of hemolytic uremic syndrome. Pediatr Nephrol 30:2115\u20132119","journal-title":"Pediatr Nephrol"},{"key":"4025_CR10","first-page":"341860","volume":"2012","author":"P Robitaille","year":"2012","unstructured":"Robitaille P, Clermont MJ, Merouani A, Phan V, Lapeyraque AL (2012) Hemolytic uremic syndrome: late renal injury and changing incidence\u2014a single centre experience in Canada. Scientifica (Cairo) 2012:341860","journal-title":"Scientifica (Cairo)"},{"key":"4025_CR11","first-page":"352","volume":"52","author":"G Small","year":"1999","unstructured":"Small G, Watson AR, Evans JH, Gallagher J (1999) Hemolytic uremic syndrome: defining the need for long-term follow-up. Clin Nephrol 52:352\u2013356","journal-title":"Clin Nephrol"},{"key":"4025_CR12","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1086\/341940","volume":"186","author":"A Gerber","year":"2002","unstructured":"Gerber A, Karch H, Allerberger F, Verweyen HM, Zimmerhackl LB (2002) Clinical course and the role of Shiga toxin\u2013producing Escherichia coli infection in the hemolytic\u2013uremic syndrome in pediatric patients, 1997\u20132000, in Germany and Austria: a prospective study. J Infect Dis 186:493\u2013500","journal-title":"J Infect Dis"},{"key":"4025_CR13","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1371\/journal.ppat.0030147","volume":"3","author":"P Schmid-Hempel","year":"2007","unstructured":"Schmid-Hempel P, Frank SA (2007) Pathogenesis, virulence, and infective dose. PLoS Pathog 3:e147","journal-title":"PLoS Pathog"},{"key":"4025_CR14","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/j.1745-4565.2001.tb00307.x","volume":"21","author":"MH Kothary","year":"2001","unstructured":"Kothary MH, Babu US (2001) Infective dose of foodborne pathogens in volunteers: a review. J Food Saf 21:49\u201368","journal-title":"J Food Saf"},{"key":"4025_CR15","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3201\/eid1104.040739","volume":"11","author":"JM Rangel","year":"2005","unstructured":"Rangel JM, Sparling PH, Crowe C, Griffin PM, Swerdlow DL (2005) Epidemiology of Escherichia coli O157:H7 outbreaks, United States, 1982\u20132002. Emerg Infect Dis 11:603\u2013609","journal-title":"Emerg Infect Dis"},{"key":"4025_CR16","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1128\/JB.181.11.3525-3535.1999","volume":"181","author":"MP Castanie-Cornet","year":"1999","unstructured":"Castanie-Cornet MP, Penfound TA, Smith D, Elliott JF, Foster JW (1999) Control of acid resistance in Escherichia coli. J Bacteriol 181:3525\u20133535","journal-title":"J Bacteriol"},{"key":"4025_CR17","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3389\/fcimb.2013.00015","volume":"3","author":"EL Hartland","year":"2013","unstructured":"Hartland EL, Leong JM (2013) Enteropathogenic and enterohemorrhagic E. coli: ecology, pathogenesis, and evolution. Front Cell Infect Microbiol 3:15","journal-title":"Front Cell Infect Microbiol"},{"key":"4025_CR18","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1007\/s00253-015-7236-3","volume":"100","author":"YS Chan","year":"2016","unstructured":"Chan YS, Ng TB (2016) Shiga toxins: from structure and mechanism to applications. Appl Microbiol Biotechnol 100:1597\u20131610","journal-title":"Appl Microbiol Biotechnol"},{"key":"4025_CR19","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2174\/138920310790274662","volume":"11","author":"TB Ng","year":"2010","unstructured":"Ng TB, Wong JH, Wang H (2010) Recent progress in research on ribosome inactivating proteins. Curr Protein Pept Sci 11:37\u201353","journal-title":"Curr Protein Pept Sci"},{"key":"4025_CR20","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1017\/S0950268800066462","volume":"99","author":"SM Scotland","year":"1987","unstructured":"Scotland SM, Willshaw GA, Smith HR, Rowe B (1987) Properties of strains of Escherichia coli belonging to serogroup O 157 with special reference to production of Vero cytotoxins VTl and VT2. Epidemiol Infect 99:613\u2013624","journal-title":"Epidemiol Infect"},{"key":"4025_CR21","doi-asserted-by":"publisher","unstructured":"Melton-Celsa AR (2014) Shiga toxin (Stx) classification, structure, and function. Microbiol Spectr 2. https:\/\/doi.org\/10.1128\/microbiolspec.EHEC-0024-2013","DOI":"10.1128\/microbiolspec.EHEC-0024-2013"},{"key":"4025_CR22","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1182\/blood.V95.11.3396","volume":"95","author":"DMWM Loo te","year":"2000","unstructured":"te Loo DMWM, Monnens LAH, van der Velden TJAM, Vermeer MA, Preyers F, Demacker PNM, van den Heuvel LPWJ, van Hinsbergh VWM (2000) Binding and transfer of verocytotoxin by polymorphonuclear leukocytes in hemolytic uremic syndrome. Blood 95:3396\u20133402","journal-title":"Blood"},{"key":"4025_CR23","first-page":"105","volume":"357","author":"TG Obrig","year":"2012","unstructured":"Obrig TG, Karpman D (2012) Shiga toxin pathogenesis: kidney complications and renal failure. Curr Top Microbiol Immunol 357:105\u2013136","journal-title":"Curr Top Microbiol Immunol"},{"key":"4025_CR24","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1056\/NEJM200104053441406","volume":"344","author":"MJ Walport","year":"2001","unstructured":"Walport MJ (2001) Complement. N Engl J Med 344:1058\u20131066","journal-title":"N Engl J Med"},{"key":"4025_CR25","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/nrneph.2012.195","volume":"8","author":"M Noris","year":"2012","unstructured":"Noris M, Mescia F, Remuzzi G (2012) STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol 8:622\u2013633","journal-title":"Nat Rev Nephrol"},{"key":"4025_CR26","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1042\/bst0301006","volume":"30","author":"MK Pangburn","year":"2002","unstructured":"Pangburn MK, Rawal N (2002) Structure and function of complement C5 convertase enzymes. Biochem Soc Trans 30:1006\u20131010","journal-title":"Biochem Soc Trans"},{"key":"4025_CR27","first-page":"845","volume":"89","author":"Y Kim","year":"1977","unstructured":"Kim Y, Miller K, Michael AF (1977) Breakdown products of C3 and factor B in hemolytic\u2013uremic syndrome. J Lab Clin Med 89:845\u2013850","journal-title":"J Lab Clin Med"},{"key":"4025_CR28","first-page":"168","volume":"13","author":"L Monnens","year":"1980","unstructured":"Monnens L, Molenaar J, Lambert PH, Proesmans W, van Munster P (1980) The complement system in hemolytic\u2013uremic syndrome in childhood. Clin Nephrol 13:168\u2013171","journal-title":"Clin Nephrol"},{"key":"4025_CR29","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/cei.12601","volume":"181","author":"JR Ferraris","year":"2015","unstructured":"Ferraris JR, Ferraris V, Acquier AB, Sorroche PB, Saez MS, Ginaca A, Mendez CF (2015) Activation of the alternative pathway of complement during the acute phase of typical haemolytic uraemic syndrome. Clin Exper Immunol 181:118\u2013125","journal-title":"Clin Exper Immunol"},{"key":"4025_CR30","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s00467-016-3496-0","volume":"32","author":"D Westra","year":"2017","unstructured":"Westra D, Volokhina EB, van der Molen RG, van der Velden TJAM, Jeronimus-Klaasen A, Goertz J, Gracchi V, Dorresteijn EM, Bouts AHM, Keijzer-Veen MG, van Wijk JAE, Bakker JA, Roos A, van den Heuvel LP, van de Kar NCAJ (2017) Serological and genetic complement alterations in infection-induced and complement-mediated hemolytic uremic syndrome. Pediatr Nephrol 32:297\u2013309","journal-title":"Pediatr Nephrol"},{"key":"4025_CR31","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.2215\/CJN.02730409","volume":"4","author":"JM Thurman","year":"2009","unstructured":"Thurman JM, Marians R, Emlen W, Wood S, Smith C, Akana H, Holers VM, Lesser M, Kline M, Hoffman C, Christen E, Trachtman H (2009) Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol 4:1920\u20131924","journal-title":"Clin J Am Soc Nephrol"},{"key":"4025_CR32","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.4049\/jimmunol.1402470","volume":"194","author":"I Arvidsson","year":"2015","unstructured":"Arvidsson I, Stahl AL, Hedstrom MM, Kristoffersson AC, Rylander C, Westman JS, Storry JR, Olsson ML, Karpman D (2015) Shiga toxin-induced complement-mediated hemolysis and release of complement-coated red blood cell-derived microvesicles in hemolytic uremic syndrome. J Immunol 194:2309\u20132318","journal-title":"J Immunol"},{"key":"4025_CR33","doi-asserted-by":"publisher","first-page":"5503","DOI":"10.1182\/blood-2010-09-309161","volume":"117","author":"AL Stahl","year":"2011","unstructured":"Stahl AL, Sartz L, Karpman D (2011) Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome. Blood 117:5503\u20135513","journal-title":"Blood"},{"key":"4025_CR34","doi-asserted-by":"publisher","first-page":"6394","DOI":"10.4049\/jimmunol.0900151","volume":"182","author":"D Orth","year":"2009","unstructured":"Orth D, Khan AB, Naim A, Grif K, Brockmeyer J, Karch H, Joannidis M, Clark SJ, Day AJ, Fidanzi S, Stoiber H, Dierich MP, Zimmerhackl LB, W\u00fcrzner R (2009) Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome. J Immunol 182:6394\u20136400","journal-title":"J Immunol"},{"key":"4025_CR35","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1128\/IAI.01079-12","volume":"81","author":"S Ehrlenbach","year":"2013","unstructured":"Ehrlenbach S, Rosales A, Posch W, Wilflingseder D, Hermann M, Brockmeyer J, Karch H, Satchell SC, Wurzner R, Orth-Holler D (2013) Shiga toxin 2 reduces complement inhibitor CD59 expression on human renal tubular epithelial and glomerular endothelial cells. Infect Immun 81:2678\u20132685","journal-title":"Infect Immun"},{"key":"4025_CR36","doi-asserted-by":"publisher","first-page":"172","DOI":"10.4049\/jimmunol.1100491","volume":"187","author":"M Morigi","year":"2011","unstructured":"Morigi M, Galbusera M, Gastoldi S, Locatelli M, Buelli S, Pezzotta A, Pagani C, Noris M, Gobbi M, Stravalaci M, Rottoli D, Tedesco F, Remuzzi G, Zoja C (2011) Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. J Immunol 187:172\u2013180","journal-title":"J Immunol"},{"key":"4025_CR37","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1681\/ASN.2013050450","volume":"25","author":"M Locatelli","year":"2014","unstructured":"Locatelli M, Buelli S, Pezzotta A, Corna D, Perico L, Tomasoni S, Rottoli D, Rizzo P, Conti D, Thurman JM, Remuzzi G, Zoja C, Morigi M (2014) Shiga toxin promotes podocyte injury in experimental hemolytic uremic syndrome via activation of the alternative pathway of complement. J Am Soc Nephrol 25:1786\u20131798","journal-title":"J Am Soc Nephrol"},{"key":"4025_CR38","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/nbt1344","volume":"25","author":"RP Rother","year":"2007","unstructured":"Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L (2007) Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 25:1256\u20131264","journal-title":"Nat Biotechnol"},{"key":"4025_CR39","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/ki.2014.423","volume":"87","author":"C Licht","year":"2015","unstructured":"Licht C, Greenbaum LA, Muus P, Babu S, Bedrosian CL, Cohen DJ, Delmas Y, Douglas K, Furman RR, Gaber OA, Goodship T, Herthelius M, Hourmant M, Legendre CM, Remuzzi G, Sheerin N, Trivelli A, Loirat C (2015) Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int 87:1061\u20131073","journal-title":"Kidney Int"},{"key":"4025_CR40","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.kint.2015.11.026","volume":"89","author":"LA Greenbaum","year":"2016","unstructured":"Greenbaum LA, Fila M, Ardissino G, Al-Akash SI, Evans J, Henning P, Lieberman KV, Maringhini S, Pape L, Rees L, van de Kar NCAJ, Vande Walle J, Ogawa M, Bedrosian CL, Licht C (2016) Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int 89:701\u2013711","journal-title":"Kidney Int"},{"key":"4025_CR41","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","volume":"368","author":"CM Legendre","year":"2013","unstructured":"Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, N\u00fcrnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C (2013) Terminal complement inhibitor eculizumab in atypical hemolytic\u2013uremic syndrome. N Engl J Med 368:2169\u20132181","journal-title":"N Engl J Med"},{"key":"4025_CR42","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1056\/NEJMc1100859","volume":"364","author":"AL Lapeyraque","year":"2011","unstructured":"Lapeyraque AL, Malina M, Fremeaux-Bacchi V, Boppel T, Kirschfink M, Oualha M, Proulx F, Clermont MJ, Le Deist F, Niaudet P, Schaefer F (2011) Eculizumab in severe Shiga-toxin-associated HUS. N Engl J Med 364:2561\u20132563","journal-title":"N Engl J Med"},{"key":"4025_CR43","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1056\/NEJMoa1106482","volume":"365","author":"U Buchholz","year":"2011","unstructured":"Buchholz U, Bernard H, Werber D, B\u00f6hmer MM, Remschmidt C, Wilking H, Deler\u00e9 Y, an der Heiden M, Adlhoch C, Dreesman J, Ehlers J, Ethelberg S, Faber M, Frank C, Fricke G, Greiner M, H\u00f6hle M, Ivarsson S, Jark U, Kirchner M, Koch J, Krause G, Luber P, Rosner B, Stark K, K\u00fchne M (2011) German outbreak of Escherichia coli O104:H4 associated with sprouts. N Engl J Med 365:1763\u20131770","journal-title":"N Engl J Med"},{"key":"4025_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/kisup.2012.1","volume":"2","author":"JA Kellum","year":"2012","unstructured":"Kellum JA, Lameire N, Aspelin P, Barsoum RS, Burdmann EA, Goldstein SL, Herzog CA, Joannidis M, Kribben A, Levey AS, MacLeod AM, Mehta RL, Murray PT, Naicker S, Opal SM, Schaefer F, Schetz M, Uchino S (2012) Kidney disease: improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl 2:1\u2013138","journal-title":"Kidney Int Suppl"},{"key":"4025_CR45","unstructured":"Deutsche Gesellschaft f\u00fcr Nephrologie (2011) Advice of the German Society of Nephrology on the use of ecilizumab during the 2011 EHEC HUS outbreak"},{"key":"4025_CR46","doi-asserted-by":"publisher","first-page":"3807","DOI":"10.1093\/ndt\/gfs394","volume":"27","author":"JT Kielstein","year":"2012","unstructured":"Kielstein JT, Beutel G, Fleig S, Steinhoff J, Meyer TN, Hafer C, Kuhlmann U, Bramstedt J, Panzer U, Vischedyk M, Busch V, Ries W, Mitzner S, Mees S, Stracke S, N\u00fcrnberger J, Gerke P, Wiesner M, Sucke B, Abu-Tair M, Kribben A, Klause N, Schindler R, Merkel F, Schnatter S, Dorresteijn EM, Samuelsson O, Brunkhorst R (2012) Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic\u2013uraemic syndrome: an analysis of the German STEC-HUS registry. Nephrol Dial Transplant 27:3807\u20133815","journal-title":"Nephrol Dial Transplant"},{"key":"4025_CR47","doi-asserted-by":"publisher","first-page":"e4565","DOI":"10.1136\/bmj.e4565","volume":"345","author":"J Menne","year":"2012","unstructured":"Menne J, Nitschke M, Stingele R, Abu-Tair M, Beneke J, Bramstedt J, Bremer JP, Brunkhorst R, Busch V, Dengler R, Deuschl G, Fellermann K, Fickenscher H, Gerigk C, Goettsche A, Greeve J, Hafer C, Hagenm\u00fcller F, Haller H, Herget-Rosenthal S, Hertenstein B, Hofmann C, Lang M, Kielstein JT, Klostermeier UC, Knobloch J, Kuehbacher M, Kunzendorf U, Lehnert H, Manns MP, Menne TF, Meyer TN, Michael C, M\u00fcnte T, Neumann-Grutzeck C, Nuernberger J, Pavenstaedt H, Ramazan L, Renders L, Repenthin J, Ries W, Rohr A, Rump LC, Samuelsson O, Sayk F, BMW S, Schnatter S, Sch\u00f6cklmann H, Schreiber S, von Seydewitz CU, Steinhoff J, Stracke S, Suerbaum S, van de Loo A, Vischedyk M, Weissenborn K, Wellh\u00f6ner P, Wiesner M, Zeissig S, B\u00fcning J, Schiffer M, Kuehbacher T, EHEC-HUS consortium (2012) Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case\u2013control study. BMJ 345:e4565","journal-title":"BMJ"},{"key":"4025_CR48","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1093\/cid\/cis531","volume":"55","author":"S Loos","year":"2012","unstructured":"Loos S, Ahlenstiel T, Kranz B, Staude H, Pape L, Hartel C, Vester U, Buchtala L, Benz K, Hoppe B, Beringer O, Krause M, Muller D, Pohl M, Lemke J, Hillebrand G, Kreuzer M, Konig J, Wigger M, Konrad M, Haffner D, Oh J, Kemper MJ (2012) An outbreak of Shiga toxin-producing Escherichia coli O104:H4 hemolytic uremic syndrome in Germany: presentation and short-term outcome in children. Clin Infect Dis 55:753\u2013759","journal-title":"Clin Infect Dis"},{"key":"4025_CR49","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1093\/cid\/cix218","volume":"64","author":"S Loos","year":"2017","unstructured":"Loos S, Aulbert W, Hoppe B, Ahlenstiel-Grunow T, Kranz B, Wahl C, Staude H, Humberg A, Benz K, Krause M, Pohl M, Liebau MC, Schild R, Lemke J, Beringer O, M\u00fcller D, H\u00e4rtel C, Wigger M, Vester U, Konrad M, Haffner D, Pape L, Oh J, Kemper MJ (2017) Intermediate follow-up of pediatric patients with hemolytic uremic syndrome during the 2011 outbreak caused by E. coli O104:H4. Clin Infect Dis 64:1637\u20131643","journal-title":"Clin Infect Dis"},{"key":"4025_CR50","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1053\/j.ajkd.2008.07.038","volume":"53","author":"M Michael","year":"2009","unstructured":"Michael M, Elliott EJ, Craig JC, Ridley G, Hodson EM (2009) Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: a systematic review of randomized controlled trials. Am J Kidney Dis 53:259\u2013272","journal-title":"Am J Kidney Dis"},{"key":"4025_CR51","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/QCO.0000000000000279","volume":"29","author":"E Benamu","year":"2016","unstructured":"Benamu E, Montoya JG (2016) Infections associated with the use of eculizumab: recommendations for prevention and prophylaxis. Curr Opin Infect Dis 29:319\u2013329","journal-title":"Curr Opin Infect Dis"},{"key":"4025_CR52","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1093\/ndt\/gft470","volume":"29","author":"Y Delmas","year":"2014","unstructured":"Delmas Y, Vendrely B, Clouzeau B, Bachir H, Bui H-N, Lacraz A, H\u00e9lou S, Bordes C, Reffet A, Llanas B, Skopinski S, Rolland P, Gruson D, Combe C (2014) Outbreak of Escherichia coli O104:H4 haemolytic uraemic syndrome in France: outcome with eculizumab. Nephrol Dial Transplant 29:565\u2013572","journal-title":"Nephrol Dial Transplant"},{"key":"4025_CR53","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1001\/jama.290.10.1360","volume":"290","author":"AX Garg","year":"2003","unstructured":"Garg AX, Suri RS, Barrowman N, Rehman F, Matsell D, Rosas-Arellano MP, Salvadori M, Haynes RB, Clark WF (2003) Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression. JAMA 290:1360\u20131370","journal-title":"JAMA"},{"key":"4025_CR54","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/dmcn.12161","volume":"55","author":"C Gitiaux","year":"2013","unstructured":"Gitiaux C, Krug P, Grevent D, Kossorotoff M, Poncet S, Eisermann M, Oualha M, Boddaert N, Salomon R, Desguerre I (2013) Brain magnetic resonance imaging pattern and outcome in children with haemolytic\u2013uraemic syndrome and neurological impairment treated with eculizumab. Dev Med Child Neurol 55:758\u2013765","journal-title":"Dev Med Child Neurol"},{"key":"4025_CR55","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.hkjn.2014.07.001","volume":"16","author":"Z Ekinci","year":"2014","unstructured":"Ekinci Z, Bek K, Aytac MB, Karadenizli A, Hancer VS (2014) Renal outcome with eculizumab in two diarrhea-associated hemolytic\u2013uremic syndrome cases with severe neurologic involvement. Hong Kong J Nephrol 16:46\u201349","journal-title":"Hong Kong J Nephrol"},{"key":"4025_CR56","doi-asserted-by":"publisher","first-page":"e1000","DOI":"10.1097\/MD.0000000000001000","volume":"94","author":"L Pape","year":"2015","unstructured":"Pape L, Hartmann H, Bange FC, Suerbaum S, Bueltmann E, Ahlenstiel-Grunow T (2015) Eculizumab in typical hemolytic uremic syndrome (HUS) with neurological involvement. Medicine 94:e1000","journal-title":"Medicine"},{"key":"4025_CR57","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.2215\/CJN.08921209","volume":"5","author":"S Nathanson","year":"2010","unstructured":"Nathanson S, Kwon T, Elmaleh M, Charbit M, Launay EA, Harambat J, Brun M, Ranchin B, Bandin F, Cloarec S, Bourdat-Michel G, Pi\u00e8trement C, Champion G, Ulinski T, Desch\u00eanes G (2010) Acute neurological involvement in diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol 5:1218\u20131228","journal-title":"Clin J Am Soc Nephrol"},{"key":"4025_CR58","doi-asserted-by":"crossref","unstructured":"Schwartz GJ, Munoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL (2009) New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20:629\u2013637","DOI":"10.1681\/ASN.2008030287"},{"key":"4025_CR59","doi-asserted-by":"crossref","unstructured":"Akcan-Arikan A, Zappitelli M, Loftis LL, Washburn KK, Jefferson LS, Goldstein SL (2007) Modified RIFLE criteria in critically ill children with acute kidney injury. Kidney Int 71:1028\u20131035","DOI":"10.1038\/sj.ki.5002231"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-018-4025-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00467-018-4025-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-018-4025-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T19:23:41Z","timestamp":1720466621000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00467-018-4025-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,30]]},"references-count":59,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["4025"],"URL":"https:\/\/doi.org\/10.1007\/s00467-018-4025-0","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,30]]},"assertion":[{"value":"18 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"PW none, SJ - member of scientific advisory board for Global aHUS registry (sponsor: Alexion Pharaceuticals).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}